Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. by Shan, S. Q. et al.
British Joumal ofCancer(1997) 76(4), 429-437
© 1997 Cancer Research Campaign
Effects of diethylaminelnitric oxide on blood perfusion
and oxygenation in the R323OAc mammary carcinoma
SQ Shan', GL Rosner2, RD Braun', J Hahn', C Pearce' and MW Dewhirst1
'Department of Radiation Oncology, 2Division of Biometry, Department of Community and Family Medicine, Duke University Medical Center, Durham,
NC 27710, USA
Summary The effects of intravenous diethylamine/nitric oxide (DEANNO), a short-acting nitric oxide (NO) donor, on systemic
haemodynamics, muscle and tumour blood flow (MBF and TBF) and tumour oxygenation were examined in rats bearing subcutaneous
R3230Ac carcinoma in the leg. The effects of DEA/NO on the diameters of tumour-feeding and normal arterioles were evaluated in window
chambers with and without implanted tumours. DEA/NO reduced mean arterial pressure (MAP) when given at doses .100 nmol kg-1, with
maximal suppression at 0.5-1 min followed by return to baseline within 20 min. DEA/NO did not affect MBF except at the highest doses (500
and 1000 nmol kg-'). In contrast, DEANNO reduced TBF and constricted tumour arterioles at doses .100 nmol kg-'. Tumour arteriolar
vasomotion occurred in more than half the animals during hypotension and with a significantly higher frequency than in normal granulating
tissue at a dose of 500 nmol kg-'. Normal arterioles rapidly and significantly vasodilated for about 3 min and then returned to baseline. The
reductions in TBF and MAP were accompanied by synchronous reduction in tumour P02- Our findings suggest that DEA/NO decreases TBF
in two ways. In the window chamber model, vascular steal occurs as normal arterioles adjacent to tumour dilate more than tumour arterioles
during the initial period of hypotension. In leg tumours, the predominant mechanism is attributable to reduced perfusion pressure induced by
lowered MAP, which decreases flow to the tumour, probably because of relatively higher flow resistance. The vasoconstriction and
vasomotion in tumour arterioles during DEANNO-induced hypotension may reflect differences in regulatory metabolism of NO between
neoplastic and normal arterioles. Thus, intravenous injection of a short-acting NO donor, DEANNO, decreases MAP and heart rate, leading to
subsequent decreases in tumour blood flow and oxygenation.
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The relatively recent discovery that nitric oxide (NO) is a primary
mediator of vascular tone has raised interest in its effects on
tumour blood flow and oxygenation. It has previously been
demonstrated that systemic or local administration ofinhibitors of
nitric oxide synthase (NOS) leads to reduction of tumour blood
flow or bioenergetics that in some cases is relatively irreversible
compared with its effects in normal tissue (Andrade et al, 1992;
Wood et al, 1993, 1994 a, b; Meyer et al, 1995).
Nitric oxide, eitherNO gas orreleasedfromNO donors, has also
shown a radiosensitization effect in vitro (Howard-Flanders, 1957;
Mitchell et al, 1993) and in tumours in vivo (Wood etal, 1993). An
NO donor drug, diethylamine nitric oxide (DEA/NO), has been
reported to sensitize hypoxic mammalian cells to irradiation; no
sensitization was seen in aerobic cells (Mitchell et al, 1993). This
NO-mediated hypoxic radiosensitization has been shown to be
similar to that of oxygen (Howard-Flanders, 1957; Mitchell et al,
1993). Use of the same drug, however, has been demonstrated to
protect mice against whole-body irradiation, and the effect was
thought to be due to induction of hypoxia in bone marrow as a
result of tissue perfusion changes (Liebmann et al, 1994). In a
previous study, DEA/NO administration caused a slight reduction
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in tumour oxygen tension, which was speculated to be due to a
vascular steal effect (Song et al, 1995). The ultimate use of NO
donors in the clinic will depend on careful examination of the
physiological effects of such agents and determination of whether
they can be used safely in patients at doses that are needed to
achieve radiosensitization. Such information is not currently avail-
able for NO donor drugs.
The purpose of this study was to investigate the effects of
varying doses ofDEA/NO on systemic haemodynamics, arteriolar
diameter and blood perfusion in tumour and normal tissues, as
well as the effect on tumour oxygention. The hypothesis of the
study was that systemic changes in cardiovascular function
induced by DEA/NO administration would lead to alterations in
tumour perfusion and oxygenation.
MATERIALS AND METHODS
Animal model
Fischer-344 rats (Charles River Laboratories, Raleigh, NC, USA)
weighing 130-180 g were used for all experiments. Animals were
allowed access to rodent chow and water ad libitum before experi-
ments. The protocol was approved by the Duke University Animal
Care and Use Committee.
For laser Doppler flowmetry and tumour oxygenation experi-
ments, a 0.5- to 1.0-mm piece ofR3230Ac mammary adenocarci-
noma was transplanted subcutaneously onto the left hind leg.
Animals were used for experiments when the tumours grew to
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around 10 mm in diameter. Transparent dorsal skinfold window
chambers, surgically prepared 8-9 days before experimentation,
were used to visualize arterioles feeding tumours or granulating
subcutaneous tissues. The tumours averaged 2-3 mm diameter at
the time of experimentation. Details of the window chamber
surgery and tumour transplantation have been described previ-
ously (Papenfuss et al, 1979).
DEA/NO
A recently developed series of compounds, the NO/nucleophile
complexes (NONOates), are capable of spontaneously, non-enzy-
matically generating NO both in vitro and in vivo in predictable
amounts and at predictable rates. Among these NONOates,
diethylamine nitric oxide (DEA/NO) exerts the most potent and
fastest vasorelaxing effect and also has the highest molar genera-
tion ofNO (Diodati et al, 1993). The DEA/NO used for this study
was a gift from Dr LK Keefer, Laboratory of Comparative
Carcinogenesis, NCI, Frederick Cancer and Development Centre,
Frederick, MD, USA. This compound is relatively stable in solid
form, but first-order decomposition occurs when it is dissolved in
aqueous media at physiological pH. Solid DEA/NO was stored in
a freezer at -20°C. Stock solutions (1 mm for lower doses and
10 mm for higher doses) were freshly prepared before experiments
by dissolving the drug in ice-cold 0.01 M sodium hydroxide and
storing on ice after preparation to minimize decomposition. Stock
solutions were kept no longer than 3 h before use. This was
because its half-life at 37°C in pH 7.4 buffer is reported to be
2.1 min (Diodati et al, 1993). Aliquots ofpremeasured amounts of
0.1 M phosphate-buffered saline (PBS, pH 7.4) were put in a water
bath at 370C and used for a quick one-step dilution of DEA/NO
solution immediately before use. Doses examined were 10, 50,
100, 500 and 1000 nmol kg-'. PBS and decomposed DEA/NO
(PBS diluted 0.5 mm DEAINO at the same concentration as forthe
dose of 1000 nmol kg-', incubated at 370C for more than 1.5 h)
were used as control solutions. The injected volume for all test
solutions and doses was 2.0 ml kg-' body weight; all solutions
were injected i.v. as a bolus over 7-10 s.
Laser Doppler flowmetry
A single-channel laser Dopplerflowmeter (LDF) (LaserFlow BPM
403A, TSI, St Paul, MN, USA) was used forevaluation ofchanges
in tumour blood perfusion. It was connected to a microcomputer
(Zenith Data Systems, model 2BV-3339-KQ, Benton Harbor, MI,
USA) equipped with data acquisition software (CODAS; DATAQ
Instruments, Akron, OH, USA) interfaced to Digital 1/0 analogue
output (DATAQ model DI-40). A needle probe (0.8 mm in diam-
eter; Vasamedic, St Paul, MN, USA) was gently inserted into the
central area of the tumour through an 18G catheter (Baxterm
Baxter Health Care Corporation, Deerfield, IL, USA) that was
preplaced to the desired intratumoral location, using techniques
previously described (Acker et al, 1990). A 1.0-mm-diameter
probe was placed into a small skin incision over the gastrocnemius
muscle proximal to the tumour to measure muscle blood flow.
Probe tips were moistened with heparinized saline (20 U ml-l)
before insertion into tissue. All probes were secured by taping
them to a Plexiglas stage, which maintained them in a stable posi-
tion without pressure on the tissue. During experiments, the probes
were sequentially connected to the LaserFlow device for data
recording (10-15 s for each probe location). The resultant data are
reported as relative changes in flow, as this device is not calibrated
for perfusion measurements in tumour tissues (Song et al, 1987).
Arteriolar diameter measurements
Anaesthetized rats with window chambers were placed in right
lateral recumbency on a microscope stage (Zeiss Photomicroscope
III, Carl Zeiss, New York, NY, USA). The window preparations
were observed by transillumination with a 40-W tungsten light
source at x 200. Tumour feeding arterioles were visualized by
examining the subcutaneous vascular bed that resides beneath the
tumour. We have defined the criteria for determining arterioles in
this model system as: (1) visualization of smooth muscle wall; (2)
straight path with fewbranches; (3) direct observation ofdivergent
flow; and (4) for tumour arterioles, divergent flow must traverse
into the tumour mass (Dewhirst et al, 1994). Images of focused
vessels were captured with a video camera (CCD-72, Dage MTI,
Michigan City, IN, USA) and recorded on SVHS videotape
(Model BV-1000, Mitsubishi Electronics, Japan). A video-timer
signal (ForA., Lid. Model VTG-55, Los Angeles, CA, USA) was
superimposed on the images for record keeping. For arteriolar
diameter measurements, the videotaped images were analysed
with an Image Shearing Monitor (Model 907, Instrumentation for
Physiology & Medicine, San Diego, CA, USA) as previously
described (Dewhirst et al, 1989).
Analysis for vasomotion
For the first 10 min after DEA/NO administration, arteriolar diam-
eters were measured every 30 s and for all maxima and minima of
the vasomotion cycles. Relative changes in arteriolardiameter were
plotted as a function of time of observation. Vasomotion cycles
were defined as a diameter change between sequential maxima or
minima (peak to peak or valley to valley) that were larger than a
'threshold' value. For arterioles with baseline diameters less than
20 jim, this was defined as > 5% change in diameter. For arterioles
with baseline diameters greater than 20gim, the threshold was set at
2 ,um. To quantify the difference in vasomotor frequency between
tumour and granulating tissue arterioles, we compared the
following parameters: (1) number of cycles during the 10-min
period ofobservation and (2) frequency of vasomotion, defined as
the number ofcycles divided by the overall time ofobservation.
Tumour oxygenation measurements
Recessed-tip oxygen microelectrodes, with 6 to 20-jm-diameter
tips were manufactured in our laboratory using the method of
Linsenmeier and Yancey (1987). The cathodes were coated with a
gas-permeable membrane (Rhoplex; Rohm and Haas, Philadelphia,
PA, USA) to prevent possible electrode poisoning. Electrode
current was measured with a microsensor (Chemical Microsensor,
Model 1201; Diamond General, Ann Arbor, MI, USA) and the
output was connected to a PC computer equipped with the CODAS
software described above. Each electrode was calibrated against
four standard gases two orthree times before use in vivo in order to
determine linearity and reproducibility of response; calibrations
were also performed after experimentation to again confirm
linearity. Conversion of current to oxygen partial pressure (p02)
was accomplished using the in vitro calibration line, which also
included an in vivo value recorded in the tumour after death
(Dewhirst et al, 1992b). Intratumoral measurements were made by
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inserting the electrode into the tumour mass with a micromanipu-
latorandleaving the electrode inplace fortheduration oftheexper-
imental protocol.
PO2 measurements were performed in seven leg tumour-bearing
rats following a single dose of 1000 nmol kg-'. In five rats, two
0.4-mm-diameter needle LDF probes were also inserted into the
tumour before the oxygen electrode. The LDF was measured
continuously throughout the experiments, using the Oxford Array
System (Oxford Optronix, Oxford, UK).
Experimental protocols
Four groups of rats were used to study: (1) blood flow in leg
tumours and adjacent muscle with LDF (n = 13); (2) changes in
diameteroftumour-feeding arterioles (n = 12); (3) changes in arte-
rioles of normal granulating tissue in window chambers without
tumour (n = 5); and (4) changes in tumour oxygenationALDF in leg
tumours after DEA/NO administration (n = 7).
Animals were anaesthetized with pentobarbital sodium (Abbott
Laboratories, North Chicago, IL, USA) intraperitoneally at a dose
of40 mg kg-'. Depth ofanaesthesia was monitored by evaluation
of spontaneous animal movement and by response to stimuli
(withdrawal reflex and/or blink reflexes). Redosing ofanaesthetic
(25% of initial dose) was given 10 min before starting experi-
ments, when required. The right femoral artery was cannulated
and connected to the data acquisition system for mean arterial
pressure (MAP) and heart rate measurements. The femoral vein
was cannulated for i.v. access. The animals were kept warm on a
water thermoblanket (American Pharmaseal, Valencia, CA, USA)
or a Homeothermic Blanket Control Unit (Harvard Apparatus
Limited, Edenbridge, KY, USA) throughout experiments.
Baseline parameters were recorded for at least 10 min before
injection oftest solutions.
Aprevious report (Diodati etal, 1993) and ourpilotexperiments
demonstrated that the cardiovascular effect ofDEA/NO lasted less
than 30 min. Therefore, in order to minimize animal use, each
animal was treated with different doses (three or four injections)
and the order ofdosing was variable. At least 30 min was allowed
between the end of recording data for one dose and measurement
ofbaseline forthe next test dose. Additional doses were only given
when MAP returned to within 5% ofpretreatment values.
Because of its short half-life at physiological pH and tempera-
ture (Diodati et al, 1993), the effect of delayed administration on
NO release from DEA/NO was tested. Successive 1000 nmol kg-'
doses were injected in one window tumour-bearing rat following
10-, 20- and 30-min delays after dilution with PBS. The diluted
DEA/NO solution was kept at 37°C until injection.
Forblood flow studies, LDF recording at the tumour centre was
continued from the start ofinjection to 1 min afterthe end ofinjec-
tion for each test solution. Subsequent LDF measurements were
recorded (for 10-15 s) in the tumour and in muscle at 1, 2 and
5 min after injection and then at 5-min intervals up to 35 min after
injection.
For the arteriolar diameter study, images for baseline data were
recorded for 1 min followed by continuous recording from the
beginning of injection to 10 min after the end of DEA/NO injec-
tion. After that recordings were made every 5 min up to 35 min
after injection.
For the oxygenation/LDF study, the oxygen microelectrode and
two needle laser Doppler probes were placed in the tumour and
remained at the same sites for the entire experiment. Intratumoral
PO2 was recorded several times during the 5-15 min before
DEA/NO administration to test electrode stability. The pO2 was
continuously recorded from 20 s before DEA/NO infusion until
2 min after the end of the infusion. Then pO2 was measured for
15-20 s every minute until 5 min after infusion. Thereafter pO2
was recorded at 5 min intervals for the next 25 min. LDF in this
study was recorded continuously throughout the experiments.
These measurements were only carried out at a DEA/NO dose of
1000 nmol kg-'.
Table 1 Baseline means for MAP and heart rate for different doses and groups
MAP (mmHg) Heart rate (beats min-')
Dose (nmol kg-') Window chamber Window chamber Window chamber Window chamber
with tumour without tumour with tumour without tumour
Decomposed DEANO 109 320
(96-129)a (113-342)
n=6 n=6
110 336
10 (95-118) (305-394)
n=6 n=6
108 363
50 (103-124) (349-413)
n=5 n=5
106 114 333 355
100 (94-120) (83-118) (295-409) (304-429)
n=5 n=4 n=5 n=4
109 114 326 401
500 (96-114) (103-123) (290-362) (355-414)
n=6 n=5 n=6 n=5
108 113 345 355
1000 (105-118) (96-123) (308-410) (341-428)
n=5 n=5 n=5 n=5
aThe numbers in parentheses indicate 95% confidence limits.
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Figure 1 Effects of DEA/NO on mean arterial pressure (MAP) (A) and heart
rate (B) in rats bearing dorsal skinfold window chambers with R3230Ac
mammary carcinoma. There were no changes in MAP or heart rate after
administration of decomposed DEANO ( ), 10 or 50 nmol kg-' (not
shown). DEANO caused a rapid decrease in MAP at doses > 100 nmol kg-'.
The degree of hypotension increased with dose (P< 0.001) (100 nmol kg-',
-_; 500 nmol kg-',-z-; 1000 nmol kg-', N-). DEANO at doses 2 100 nmol
kg-' also reduced heart rate. Twenty minutes after DEAINO injection both
MAP and heart rate were close to baseline, so the data after 20 min are not
shown for clarity. Each point with error bars represents the mean and 95%
confidence limits of five or six rats.
STATISTICS
We analysed changes over time seen in MAP, heart rate and blood
flow using the logarithm of measurements divided by their corre-
sponding baseline values. In the arteriolar diameter study, several
vessels appeared to close completely at some measurements times,
leading to relative diameters equal to zero. To avoid problems
caused by taking the logarithm ofzero values, we analysed relative
change in cross-sectional area, defined as the difference between
the lumen area at some time points after infusion and the baseline
area divided by the baseline area. The cross-sectional area was
estimated by multiplying the numerical constant 7t times one-
quarter the measured vessel's diameter squared.
The data set contains correlated measurements, as animals
contributed multiple data by way of measurements of several
vessels, at several DEA/NO doses, and over time. The statistical
analyses accounted for the correlation of within-subject data by
including a subject random effect in the SAS MIXED procedure
(SAS Institute 1992). Because most profiles appeared highly non-
linear, we report statistical comparisons carried out at several key
times after the infusion (namely 0.5, 1, 2, 5, 10, and 20 min). We
used orthogonal contrasts with an approximate F-test to examine
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Figure 2 Relative changes in blood flow in leg muscle near tumour (A) and
in the subcutaneously implanted tumour (B) after administration of DEANO
as measured by laser Dopplerflowmetry (LDF). There were no significant
changes in LDF for control solutions of decomposed DEA/NO (---) or PBS
or low doses of DEANO (not shown) in either muscle or tumour. Muscle
blood flow decreased after DEANO at the two highest doses (A; see text for
details). DEANO at 2 100 nmol kg-' (100 nmol kg-', -_; 500 nmol kg-', z;
1000 nmol kg -1, V-) significantly decreased tumour blood flow (B). All
changes in LDF were not significant 20 min after DEANO injection, so the
data after 20 min are not shown. Each point with error bars represents the
mean and 95% confidence limits. For tumour blood flow data, n = 6-8 for 100
and 500 nmol kg-' doses; for 1000 nmol kg-' dose, data include rats from
pO/LDF experiments (n= 14).
the statistical significance of linear dose effects, such as whether
increasing the dose of DEA/NO produced effects of greater (or
lesser) magnitude. We adjusted for differences in baseline area
when comparing lumen areas. The significance ofchanges inpO2
from baseline was based on the Wilcoxon signed-rank test. Results
of two-sided statistical significance tests were deemed significant
at the 0.05 level.
RESULTS
Effect of time between DEAINO dilution and injection
DEA/NO rapidly releases NO once it is dissolved in a medium of
physiological pH and temperature; its half-life is reported to be
2.1 min (Diodati et al, 1993). In one tumour window chamber-
bearing rat, we tested the effect of time delay after dilution of
stock DEA/NO into PBS (pH 7.4 prewarmed at 370C) at a dose of
1000 nmol kg-'. Infusion after a 10-min delay caused a marked
drop in arterial pressure and concomitant changes in arteriolar
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Figure 3 Relative changes in arteriolar cross-sectional area in tumour and
normal granulating tissue in the dorsal skinfold window chambers after
DEA/NO administration. In normal granulating tissue (A), arterioles dilated
immediately after DEA/NO administration at doses 2 100 nmol kg-' (100 nmol
kg-', -U-; 500 nmol kg-', tY; 1000 nmol kg-', V-). Vasodilation lasted for
2-3 min. After that there was a trend towards vasoconstriction but the
changes were not significant compared with baseline. There were no
significant changes in tumour-feeding arterioles (B) after injection of
decomposed DEANNO (---) or at 10 or 50 nmol kg-' (not shown).
Significant vasoconstriction occurred immediately after DEA/NO injection at
doses 2 100 nmol kg-'. Arteriolar diameter gradually returned to baseline as
blood pressure recovered. No significant differences were observed after
20 min. Each point with bars represents the mean and 95% confidence limits
for four to six rats
diameter, but 20- and 30-min delays diminished the hypotensive
and microvascular vasoactive effects ofDEA/NO in a time-depen-
dent pattern (data not shown). An incubation ofPBS-diluted solu-
tion at 370C for 1.5 h completely abolished the cardiovascular
effects of DEAINO. For this reason, the stock drug of DEA/NO
was diluted to PBS quickly using a one-step method, and the time
interval between dilution and completion of the i.v. injection was
kept to no more than 1 min for all experiments.
Arterial pressure and heart rate
Baseline MAP and heart rates for all test DEA/NO doses in the
multidose-treated rats with leg tumours and window chambers
(with or without tumour) as well as for single dose-treated rats in
the pO2 study were similar, averaging around 100 mmHg and
350 beats min-' respectively. Table 1 summarizes the MAP and
heart rate baseline values in the groups of rats bearing window
chambers with or without tumour.
Figure 1 shows the effects of DEA/NO infusion on MAP and
heart rate in the rats bearing window chambers with tumour. MAP
dropped quickly in the animals receiving at least 100 nmol kg-'
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Figure 4 Examples of arteriolar vasomotion in tumour window chambers in
two experiments during hypotension after DEANO at the dose of 500 nmol
kg-1 (top) and 1000 nmol kg-' (bottom). The thick line with symbols in each
panel represents MAP changes and lines without symbols indicate diameter
changes of individual arterioles. Vasomotor activity seemed to be synchronic
for parent and daughter arterioles
DEAINO (Figure IA), falling to 35-40% ofbaseline by 30 s after
infusion among animals receiving 500 and 1000 nmol kg-'
DEA/NO. Two minutes after infusion, MAP was around 60% of
baseline among animals receiving these two highest doses. MAP
continued returning to baseline in these animals, reaching around
82% of baseline 10 min after drug infusion. Twenty minutes after
infusion, MAP was around 94% of baseline at these two highest
doses of DEA/NO. Control solution and low doses of DEA/NO
(10, 50 nmol kg-', data not shown) did not significantly change
MAP. The degree ofhypotension increased with dose (P < 0.001)
at each of the first five time-points examined (0.5, 1, 2, 5, and
10 min after DEA/NO infusion) but not at 20 min (P = 0.174).
All other experimental groups showed similar changes.
There were no significant changes in heart rate in controls or at
low doses of DEA/NO (<50 nmol kg-', data not shown). Higher
doses ofDEA/NO produced greater reduction in heart rate among
the tumour window experiments (P < 0.01) (Figure IB) at0.5, 1, 2
and 5 min, but not 10 or 20 min after injection. In the tumour
window chamber experiments, 1000 nmol kg-' DEA/NO produced
significant heart rate reduction to around 85% ofbaseline at 0.5, 1,
2, 5 and 10 min after injection (P < 0.01 at each time examined).
Similar changes in heart rate were observed in all other groups.
Tumour blood flow
No change in blood flow was observed after administration ofPBS
or decomposed DEA/NO in either muscle or tumour (Figure 2).
Blood flow in normal muscle decreased among animals receiving
500 and 1000 nmol kg-' DEA/NO, although not immediately
(Figure 2A). In fact, blood flow increased initially among some
animals receiving the higher doses of DEA/NO, leading to quite
heterogeneous relative-flow measurements for about the first 5 min.
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Figure 5 Comparison of vasomotor activity between tumour (m) and normal
(D) arterioles after administration of 500 nmol kg-' DEANO. The vasomotor
frequency and the total number of cycles in the first 10 min after DEANO
administration were significantly greater in tumour (17 arterioles in five
window chambers) than in normal tissues (eight arterioles in five window
chambers) (*P< 0.01)
The blood flow was 79% (P = 0.012) and 70% (P <0.001) of base-
line 10 min after injection in the 500 and 1000 nmol kg-' groups
respectively. Even at 20 min, blood flow was still only 74%
(P = 0.038) of baseline among animals receiving 1000 nmol kg-'
DEA/NO. DEA/NO doses of 100 nmol kg-' and less did notproduce
significant blood flow changes in the muscle at any time examined.
In tumours, the duration and degree of blood flow reduction
increased with DEAINO dose (Figure 2B). Tumour blood flow was
75% (P = 0.023) and 55% (P < 0.001) ofbaseline 30 s after injec-
tion of 500 and 1000 nmol kg-' DEA/NO respectively. Tumour
blood flow was between 57% and 75% ofbaseline at 1,2 and 5 min
after injection of these two highest DEA/NO doses (P < 0.001).
Tumour blood flow was still significantly reduced after DEA/NO
at these doses 10 min after the injection (75% and 83%, P = 0.003
and P = 0.013 respectively). The animals receiving 100 nmol kg-',
on the other hand, experienced a significant flow reduction to 84%
(P = 0.039) ofbaseline 2 min after injection; the changes were not
significantly different from zero at the other times checked. Blood
flow in tumours essentially retumed to baseline at all doses
examined 20 min after injection of the drug, except for animals
that received 500 nmol kg-' (relative flow 84%; P = 0.032).
Arteriolar cross-sectional area
The vasoactive response of arterioles to DEA/NO infusion in
normal granulating tissue was short-lived (Figure 3A). An
increase in diameter was observed immediately after injection of
DEA/NO at doses 2 100 nmol kg-' (P < 0.01 at 30 s and P < 0.03
at 1 min). Significant vasodilation was still evident at 2 min only
in animals treated at 1000 nmol kg-' (P = 0.01). Maximal vasodi-
lation ranged between 30% and 66% of baseline cross-sectional
area and lasted 2-3 min. At the dose of 1000 nmol kg-', DEAINO
caused 66% vasodilation 30 s after injection (P = 0.002) and the
lumen area was still 64% larger than baseline at 1 min (P = 0.009).
Although there was a trend towards vasconstriction during
recovery of MAP, the lumen areas were not statistically different
from their baseline values. The cross-sectional areas of arterioles
were not significantly different from baseline at 10 and 20 min and
thereafter.
There were no significant changes in tumour arteriolar cross-
sectional area after injection of decomposed DEAINO (Figure 3B).
Low doses (10 and 50 nmol kg-') of DEA/NO had no significant
effect on tumour arteriolar diameter (data not shown). Arteriolar
vessels constricted significantly in animals treated at doses
> 100 nmol kg-' at 2 and 5 min after the infusion (P < 0.023).
Tumour arterioles in animals treated at 500 and 1000 nmol kg-'
DEA/NO remained constricted at 10 min at these two highest doses
(P <0.023). By 20 min after injection, no significant changes from
baseline were observed. The duration ofvasoconstriction in tumours
seemed somewhat longer at the two highest doses (500 and
1000 nmol kg-') compared with 100 nmol kg-'. Whereas lumen area
oftumour arterioles in animals treated with 100 nmol kg-' DEA/NO
was around 74% ofbaseline at 1 and 2 min after injection (P = 0.002
and P = 0.004 respectively) and 93% of baseline at 10 min
(P = 0.204), in animals treated at the dose of 1000 nmol kg-'
DEA/NO arterioles had narrowed significantly 2min after DEAINO
injection (about 80% ofbaseline; P = 0.023) and were still only 87%
of baseline at 10 min (P = 0.023). The difference in relative cross-
sectional area between the 100 nmol kg-' group and the animals
treated at the two highest doses, however, was not significant at
10 min (P = 0.080). However, the animals treated with doses of at
least 100 nmol kg-' did experience significantly greater tumour arte-
riole vasoconstriction than the animals treated at the control (Figure
3B) or lower doses (10 and 50 nmol kg-', data not shown) at 2,5 and
10 min after injection (P <0.012).
As can be seen by comparing the two graphs in Figure 3, there
were substantial differences between tumour and normal tissue
arterioles in response to DEAINO at doses . 100 nmol kg-'.
Whereas normal arterioles dilated just after the infusion of
DEA/NO, tumour-feeding arterioles constricted by up to 40%. The
relative changes in lumen area were significantly different in
tumour-feeding arterioles compared with normal arterioles at 0.5,
1, 2 and 5 min after infusion (P < 0.05).
Arteriolar vasomotion
In more than half the animals treated with higher doses of
DEA/NO, there were rhythmic oscillations in tumour arteriolar
diameter that were most pronounced during the period ofhypoten-
sion and gradually recovered as MAP retumed towards baseline.
Figure 4 demonstrates examples of such arteriolar vasomotion in
two experiments at doses of 500 and 1000 nmol kg-'. In a few
cases arterioles completely constricted for intervals of a few
seconds at a time. The vasomotion for parent and daughter arteri-
oles was synchronous. A reduction in arteriolar blood flow rate
was also observed during hypotension. Intermittent reversed flow
and temporary stasis were occasionally observed, even while
arterioles were dilated.
At a dose of 500 nmol kg-', arteriolar vasomotion in normal
granulating tissue was less commonly observed than in tumour-
feeding arterioles. Vasomotor frequency averaged 2-3 times higher
in tumour arterioles than in normal arterioles at this dose
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Figure 6 Effect of DEA/NO (1000 nmol kg-') administration on intratumoral
P02 in seven leg tumour-bearing rats (n =4 at 3 and 4 minand n =7 at all
other time points) (A). In a subgroup of five rats, tumour blood flow was
measured simultaneously with P02 using laser Dopplerflowmetry throughout
the experiments (B). Immediate drops in tumour P02 and tumour blood flow
afterDEANO were almostsynchronous with thechange in mean arterial
pressure (C). There were nosignificant differences in MAP, tumour LDF or
PO2 compared with baseline 20 minafter DEANOinfusion (not shown). Each
point represents the mean ± 1 s.e.m.
(P < 0.01; Figure 5). The total number of cycles over the first
10 min was also higher in tumour than in granulating tissue
(P < 0.01; Figure 5). Interestingly, there was no significant differ-
ence in these parameters of vasomotor activity at a dose of
1000 nmolkg-', as thevasoactivity ofnormal arteriolesincreased to
the level shownby the tumour arterioles. The number ofcycles for
the first 10 min was 4.2 ± 0.8 for the tumour arterioles and
4.3 ± 0.6 for the normal arterioles. Similarly, the frequency was
0.58 ±0.06 c.p.m. and 0.75 ±0.12 c.p.m. forthe tumourand normal
arteriolesrespectively (mean ± s.e.m.; n = 5 rats in each group).
IntratumoralP02
The effects of 1000 nmolkg-' ofDEA/NO on tumouroxygenation
were determined in seven experiments. pO2 averaged 10 mnmHg
A J
before drug administration (Figure 6A). Immediately after
DEA/NO administration, intratumoral pO2 dropped by an average
of 8 mmHg and was significantly lower than baseline for 10 min
(P < 0.05). TumourpO2 was not significantly different from base-
line 15 or 20 min after DEA/NO administration. The decrease in
PO2 occurred simultaneously with decreases in tumour blood flow
(Figure 6B) and MAP (Figure 6C).
DISCUSSION
The results of this study demonstrate that DEA/NO decreases
MAP, heart rate and tumour blood flow as well as tumour arteriolar
diameter. In general, effects were seen at doses of at least
100 nmol kg-', and higher doses were associated with larger
effects. At the dose of 1000 nmol kg-' DEA/NO, the drop in blood
flow was accompanied by a substantial reduction in tumourpO2.
The decreases in MAP, tumour blood flow and pO2 occurred
synchronously. These results suggest that administration of this
type of vasodilator will result in decreased peripheral perfusion
pressure, which leads to reduction in blood flow and oxygenation
in tumours. Thus, the primary hypothesis of the study was proven.
The effect ofDEA/NO on systemic arterial pressure observed in
this study was consistent with previous reports (Diodati et al,
1993). As predicted from its rate of spontaneous NO release,
DEA/NO is a short-acting vasodilator with a duration of action
similar to that of nitroprusside (Prescott et al, 1992). At doses
> 100 nmol kg-', itcaused significant reductions in MAP and heart
rate that were dose dependent. Most other hypotensive agents
cause compensatory tachycardia as a result of baroreceptor
reflexes; thus, the negative chronotropic effect of this agent is
somewhatunique andis probably related todirecteffects ofNO on
cardiac muscle contractility (Roberts et al, 1992).
The reduction in tumour blood flow after DEA/NO administra-
tion is probably due to two factors. First, vasodilatory effects in
normal arterioles in window chambers, combined with lack of
vasodilation in tumour arterioles at the time of hypotension, are
direct evidence for a vascular steal phenomenon, at least in the
window chamber preparation. In fact, the classic definition of
this phenomenon includes these features (Dewhirst et al, 1992a).
However, a vascular steal phenomenon is not a prerequisite for
preferential reduction in tumour blood flow. We have previously
reported that theperipheral vasodilatorhydralazine inducesprefer-
ential reduction in tumour blood flow in the window chamber
tumour without concomitant normal tissue vasodilation in the
tumour bed. In this case, the predominant mechanism involved is
probably relatively higher flow resistance in tumours, which is
exacerbated when the driving pressure is reduced (Dewhirst et al,
1994; Sevick andJain, 1989). We suspect that the sustained reduc-
tion in tumour blood flow that persists beyond the normal tissue
vasodilatory stage with DEAINO is probably due to this second
mechanism, as the hypotensive effects lasted longer than the
vasodilatory effects in normal granulating subcutaneous tissue that
constituted the tumour bed. The second mechanism is probably
predominantin the leg tumours as well, because we did not see any
evidence for improvement in normal muscle blood flow that was
near tumour during the period when tumour blood flow was
reduced. If a vascular steal phenomenon had occurred in that site,
one would have expected that muscle blood flow surrounding the
tumour would have been increased as blood would have been
shunted away from the tumour and into the surrounding normal
muscle.
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Administration of DEA/NO at higher doses led to reduction in
normal muscle blood flow, although not to the same extent as in
tumour tissue. There is precedence in the literature to suggest that
similar effects are seen in bone marrow. Liebmann et al (1994),
found that DEA/NO and NOS inhibition with NG-nitro-L-arginine
exerted radioprotection against whole-body irradiation in C3H
mice. They speculated that alterations in regional blood flow and
oxygenation may underlie the changes in radiation tolerance.
It is interesting to compare the effects of DEA/NO, an NO
donor, with inhibitors of NO synthase, because the net effect of
both manipulations is a reduction in tumour blood flow, even
though they produce opposite effects in terms of affecting NO
levels. Several previous reports have shown thatinhibition ofNOS
by analogues of L-arginine leads to tumour blood flow reduction
(Andrade et al, 1992; Wood et al, 1994 a,b; Meyer et al, 1995). In
this case, the vasoconstrictive effects of NO synthase inhibition
are probably responsible for the effects, as such treatment actually
induces mild hypertension. Again, the drop in tumour blood flow
is probably exacerbated in tumours because ofrelatively high flow
resistance (Sevick and Jain, 1989). Although rapid release of NO
from DEA/NO causes substantial vasodilation in normal tissue
and reduction in systemic resistance, tumour blood perfusion
decreases because of the significant hypotensive effect. Systemic
administration of such a potent and short-acting NO donor did not
dilate tumour-feeding arterioles, instead it caused vasoconstric-
tion, which probably reflects differences in NO regulation mecha-
nisms between tumour and normal microvasculature. It may be
that tumour arterioles, unlike normal arterioles, are already maxi-
mally dilated because of excessive production of NO in solid
tumour (Doi et al, 1996) and thus lack a vasodilatory response to
exogenous NO. In addition, increased interstitial pressure in
tumour mass might result in a 'passive collapse' oftumour vessels
when intravascular pressure decreases during DEA/NO-induced
hypotension.
The induction of vasomotor responses in tumour arterioles
following DEA/NO infusion is intriguing. It is possible that the
vasomotion may reflect local autoregulatory responses to
DEA/NO-induced hypotension, lowered TBF and hypoxia.
Induction ofvasomotor activity in normal arterioles has previously
been reported in response to reduction in systemic pressure as well
as reduction in oxygenation (Bertuglia et al, 1991; Vollmar et al,
1994). However, the effect seems to be controlled at the tissue
level, rather than by systemic factors. Evidence for local control
comes from experiments in which local compression of the
femoral artery led to increased arteriolar vasomotion in dependent
muscle tissue (Schmidt et al, 1992). The effect induced by hypoxia
has been shown to be caused by enhanced endothelial cell produc-
tion ofendothelin, which is also consistent with alocal tissue effect
(Kourembanas et al, 1991). Our current results are relevant to the
notion that the vasomotor activity is locally mediated in tumours as
well. The finding that the vasoactive response in tumour is exag-
gerated compared with that in normal arterioles at a dose of
500 nmol kg' suggests that the vasoactivity threshold for tumour
arterioles may be lower than that for normal arterioles. This is
consistent with the findings ofKennovin et al (1994), who demon-
strated that vasomotor activity in excised arteries that had been
feeding implanted tumours in the epigastric pedicle had increased
vasomotor activity, compared with normal control arterioles.
It has been reported previously that administration of another
NO donor drug, SIN-1, leads to improved energy status and a
threefold improvement in radiation response of the transplanted
SCCVII/Ha tumour ofC3H mice (Wood et al, 1993). This combi-
nation of effects would lead one to believe that SIN-1 improves
tumour blood flow and hence oxygenation. However, ifthe physi-
ological effects of SIN-I are similar to those seen with DEA/NO,
the net result would be to reduce tumour blood flow and oxygena-
tion rather than increase it. However, SIN-I also releases peroxy-
nitrite and hydroxyl radicals upon degradation, which may have
other, as yet to be defined, physiological effects (Feelisch and
Stamler, 1996). Another mechanism of enhanced radiation
response with NO is the direct radiosensitizing effect. Like
oxygen, NO can bind to carbon-centred radicals and prevent repair
of radiation-induced damage and increase the cytotoxicity of
radiation (Howard-Flanders, 1957). Mitchell et al (1993) found
that DEAINO is capable of sensitizing hypoxic, not aerobic, V79
cells with enhancement ratios ranging from 1.1 to 2.4 at 0.1-1 mm
concentration. Thus, the radiosensitization effect of NO might be
independent ofchanges in tumour blood flow or oxygenation.
A brief justification needs to be made for the use of the
stationary recessed-tip microelectrodes that were used for the
oxygen measurements. The reason that we did not use the
Eppendorf system, which is available to us, is twofold: (1) we
have found that performance ofrepeated measurements ofpO2 in
the same tumour with the Eppendorfsystem leads to hypoxia from
tissue damage and (2) the time course over which the hypoxia was
expected to occur would preclude measurements with a moving
electrode device. There is potential for stationary electrodes to
consume oxygen, thereby leading to artifactually low pO2 read-
ings. We do not believe thatthis happened in this case, because the
PO2 readings in both cases were quite stable for the 5-15-min
period before DEA/NO administration. Secondly, the recessed-tip
design minimizes consumption from this type of electrode
(Schneiderman and Goldstick, 1978).
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